There is a risk of hyperkalaemia if angiotensin II
receptor antagonists are given with amiloride,
eplerenone,
spironolactone or
triamterene, particularly if other risk factors (such as advanced age, dose of
spironolactone greater than 25 mg, reduced
renal function and type II diabetes) are also present.
Some manufacturers recommend that the combinations be used cautiously and that
serum potassium should be monitored regularly. However, other manufac- turers advise against concurrent use, which seems overly cautious, if adequate precautions are taken.